Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Infosys LTD ADR (INFY): This Sleeping IT Stock is Back on Track

Page 1 of 2

The Indian Blue chip firm Infosys LTD ADR (NYSE:INFY) has discarded its sluggishness by announcing remarkable growth in its Q3 FY13 earnings and by beating analysts’ expectations. The company reported net income of $434 million against $431 million in the last quarter. Revenue, including Lodestone, rose by 5.8% from a year ago to $1,911 million, and excluding Lodestone revenues posted a 3.7% year-over-year growth at $1,872 million. In spite of the increased operating expenses, Infosys was able to maintain margins through efficiency improvements by focusing on making the right investments for profitable and sustainable growth in the long term. But the significant drivers of robust growth, which attracted my affinity towards this stock, are:

Infosys Ltd ADR (NYSE:INFY)1) 8 big outsourcing deals

With the shift in market share and rising competition from the lower margin vendors, Infosys has changed its strategy in the past few quarters. The company traded off margins to regain market share by chasing large deal flows.  Infosys closed 8 large deals (4 in the US, 3 in Europe, and 1 in India) in the quarter (TCV on US $731 million), which further enhances its strong presence in various geographies of the world. North America reported tepid growth of only 1.6% in constant currency, India grew by 44.7% sequentially, and rest of the world grew by 7.4% in constant currency. Europe grew by 14.4% in constant currency because of the Lodestone integration, which strengthens its EMEA and SAP vertical presence. I believe Infosys will gain from learning the IDEA approach of Lodestone in achieving business transformation across the project life cycle.

The major catalyst for winning the 8 deals was its consulting and systems integration business, which grew by 8.1% organically quarter-over-quarter and by 15% when including Lodestone.  The Lodestone deal helped ithe company inrease its revenue to 32.6% of the total revenue in 3Q, in comparison to 30.0% in the second quarter.  The total contract value of the products and platforms business has touched $600 million, of which over $100 million came in the third quarter. In addition, the company’s Product and Platform Space also had 14 wins across industries and geographies, which are widely adopted by 70 global clients. Pricing has also gone up by 1.8% this quarter due to the faster increase in this business.

The company has signed ~20 transformational deals over the last three quarters and will witness more in the upcoming quarters.

2) Ignition of recovery phase

In my view, the first step towards recovery was made when the company signed deals to improve its US presence – with Harley Davidson and Marsh BPO, which reflects greater willingness by the company for deals that include asset and people transfer as heavier onsite component of revenue. In addition, the closer account management model will also help the company to recoup revenue shares from top 50 accounts. As this model has already worked well for Cognizant Technology Solutions Corp (NASDAQ:CTSH) and Accenture, I believe that if Infosys is able to replicate the same, it would definitely put the company back on track.

3) Strong Client addition

Another point of attraction- Infosys added 89 clients during the last quarter, and the number of active clients grew to 776 up from 715 in Q2 FY13. This point seems pretty impressive in maintaining the growth momentum of the company.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!